Antisense Drug Against BCL-2 Effective in Animal Cancer Models

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targeted against the BCL-2 gene has proved effective against drug-resistant cancers in certain animal models of follicular lymphoma and colon cancer, the company said.

SAN DIEGO--Genta Incorporated's antisense oligonucleotide targetedagainst the BCL-2 gene has proved effective against drug-resistantcancers in certain animal models of follicular lymphoma and coloncancer, the company said.

The BCL-2 gene is overexpressed in many tumors, preventing normalapoptosis and inducing drug resistance. A phase I/II trial indrug-resistant follicular lymphoma is scheduled to begin at TheRoyal Marsden Hospital, London, by mid-year.

Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
Highlighting Challenges to Patient Treatment in Rare Lymphomas
1 expert in this video
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights from ACRO 2025
1 expert in this video
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
1 expert in this video
Precision Active Surveillance: Leveraging Genomic Testing and CCR Scores in Prostate Cancer Management
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving Landscape
Using Genetic Information to Guide Precision Medicine and Personalized Treatment in Prostate Cancer: Expert Perspectives on an Evolving Landscape
Prolaris and Beyond: How Genomic Testing Has Revolutionized Prostate Cancer Management and Treatment Decisions
Prolaris and Beyond: How Genomic Testing Has Revolutionized Prostate Cancer Management and Treatment Decisions
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Genetic Data May Inform Personalized Radiotherapy Strategies for Cancer Care
2 experts are featured in this series.
Role of MRD Status in Treatment Intensification or De-Escalation of Adjuvant Therapy
2 experts are featured in this series.
BESPOKE: ctDNA Clearance During and After ACT
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
Collaborating to Improve Prostate Cancer Survival, Health Care Utilization
Related Content
Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Adding Chemo to Radiotherapy Did Not Improve Survival Outcomes in Cervical Cancer

Tim Cortese
April 15th 2025
Article

The addition of chemotherapy to radiotherapy did not show significant improvements in OS when compared with radiotherapy alone in patients with intermediate-risk cervical cancer.

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Fostering The Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Pembrolizumab/Docetaxel Doesn’t Improve OS/rPFS Outcomes in mCRPC

Tim Cortese
April 15th 2025
Article

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Elevating the Quality of Cancer Care via Cross-Department Collaboration

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD
April 7th 2025
Podcast

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

Charlotta Wadsten;Karuna Mittal;Pat W. Whitworth;Chirag Shah, MD;Frank Vicini, MD;Naamit Gerber;Melissa Krystel-Whittemore;Clayton C. Yates;Balasubramanyam Karanam;Walter Bell;Charles E. Cox, MS, FACS;Abigail Beard;Geza Acs;Steven C. Shivers;David J. Dabbs;Jess Savala;Mark Mentrikoski;Troy Bremer
April 14th 2025
Article
Miami Breast Cancer Conference Provided Exciting Updates and Engaging Discussions

Miami Breast Cancer Conference Provided Exciting Updates and Engaging Discussions

Neil M. Iyengar, MD
April 14th 2025
Article

Neil M. Iyengar, MD, discussed the most prevalent discussions and exciting updates from the 2025 Miami Breast Cancer Conference.